基于缺氧诱导因子通路治疗肾癌的研究进展
Research Progress of Treatment of Renal Cell Carcinoma Based on Hypoxia Inducible Factor Pathway
DOI: 10.12677/acm.2024.1461783, PDF,   
作者: 马锦容：延安大学医学院，陕西 延安；靳永胜*：延安大学附属医院泌尿外科，陕西 延安
关键词: 缺氧诱导因子通路；肾癌；贝组替凡；Hypoxia Inducible Factor Pathway； Renal Cell Carcinoma； Belzutifan
摘要: 肾癌是泌尿系常见恶性肿瘤之一，除外科手术外，其治疗手段包括免疫治疗、靶向治疗、以及细胞疗法等。目前缺氧诱导因子通路治疗肾细胞癌的研究取得了一定的进展，但仍面临许多挑战。本文结合国内外研究报道，针对利用缺氧诱导因子通路治疗肾癌的相关文献进行综述，旨在探讨缺氧诱导因子通路在治疗肾癌研究及应用，以期为探索肾癌治疗提供新的思路，并为肾癌治疗的相关研究提供一定价值。
Abstract: Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, in addition to surgery, its treatment includes immunotherapy, targeted therapy, cell therapy and so on. At present, some progress has been made in the treatment of renal cell carcinoma by hypoxia inducible factor pathway, but there are still many challenges. Combined with the research reports at home and abroad, this paper reviews the relevant literature on the treatment of renal cell carcinoma with hypoxia-inducible factor pathway, in order to explore the research and application of hypoxia-inducible factor pathway in the treatment of renal cell carcinoma, in order to provide new ideas for the treatment of renal cell carcinoma, and provide some value for the treatment of renal cell carcinoma.
文章引用：马锦容, 靳永胜. 基于缺氧诱导因子通路治疗肾癌的研究进展[J]. 临床医学进展, 2024, 14(6): 353-358. https://doi.org/10.12677/acm.2024.1461783

参考文献

[1] Motzer, R.J., Jonasch, E., Agarwal, N., et al. (2022) Kidney Cancer, Version 3. 2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 71-90.
[2] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[3] Moch, H., Cubilla, A.L., Humphrey, P.A., Reuter, V.E. and Ulbright, T.M. (2016) The 2016 Who Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. European Urology, 70, 93-105. [Google Scholar] [CrossRef] [PubMed]
[4] Bukowski, R.M. (1997) Natural History and Therapy of Metastatic Renal Cell Carcinoma. Cancer, 80, 1198-1220. [Google Scholar] [CrossRef] 
[5] National Comprehensive Cancer Network (2023) Kidney Cancer (v.1.2024).
https://www.nccnchina.org.cn/guide/detail/406
[6] Ahmed, R. and Ornstein, M.C. (2023) Targeting HIF-2 Alpha in Renal Cell Carcinoma. Current Treatment Options in Oncology, 24, 1183-1198. [Google Scholar] [CrossRef] [PubMed]
[7] 曹铮, 冯林, 冯晓莉. 缺氧相关的miRNA-210在肿瘤中的研究进展[J]. 肿瘤防治研究, 2018, 45(7): 500-504.
[8] Xu, R., Wang, K., Rizzi, J.P., et al. (2019) 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. Journal of Medicinal Chemistry, 62, 6876-6893. [Google Scholar] [CrossRef] [PubMed]
[9] Choueiri, T.K., Bauer, T.M., Papadopoulos, K.P., Plimack, E.R., Merchan, J.R., McDermott, D.F., et al. (2021) Inhibition of Hypoxia-Inducible Factor-2α in Renal Cell Carcinoma with Belzutifan: A Phase 1 Trial and Biomarker Analysis. Nature Medicine, 27, 802-805. [Google Scholar] [CrossRef] [PubMed]
[10] Musleh Ud Din, S., Streit, S.G., Huynh, B.T., Hana, C., Abraham, A. and Hussein, A. (2024) Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer. International Journal of Molecular Sciences, 25, Article No. 2060. [Google Scholar] [CrossRef] [PubMed]
[11] Yue, Y., Tang, Y., Huang, H., Zheng, D., Liu, C., Zhang, H., et al. (2023) VBP1 Negatively Regulates Chip and Selectively Inhibits the Activity of Hypoxia-Inducible Factor (HIF)-1α but Not HIF-2α. Journal of Biological Chemistry, 299, Article ID: 104829. [Google Scholar] [CrossRef] [PubMed]
[12] Peng, S., Wang, Z., Tang, P., Wang, S., Huang, Y., Xie, Q., et al. (2023) PHF8-GLUL Axis in Lipid Deposition and Tumor Growth of Clear Cell Renal Cell Carcinoma. Science Advances, 9, eadf3566. [Google Scholar] [CrossRef] [PubMed]
[13] Zhang, X., Li, S., He, J., Jin, Y., Zhang, R., Dong, W., et al. (2022) TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. Cancer Research, 82, 2097-2109. [Google Scholar] [CrossRef] [PubMed]
[14] Rivas, S., Silva, P., Reyes, M., Sepúlveda, H., Solano, L., Acuña, J., et al. (2020) The RabGEF ALS2 Is a Hypoxia Inducible Target Associated with the Acquisition of Aggressive Traits in Tumor Cells. Scientific Reports, 10, Article No. 22302. [Google Scholar] [CrossRef] [PubMed]
[15] Gu, X., Meng, H., Wang, J., Wang, R., Cao, M., Liu, S., et al. (2021) Hypoxia Contributes to Galectin-3 Expression in Renal Carcinoma Cells. European Journal of Pharmacology, 890, Article ID: 173637. [Google Scholar] [CrossRef] [PubMed]
[16] Liu, G., Lu, Y., Li, L., Jiang, T., Chu, S., Hou, P., et al. (2020) The Kinesin Motor Protein KIF4A as a Potential Therapeutic Target in Renal Cell Carcinoma. Investigational New Drugs, 38, 1730-1742. [Google Scholar] [CrossRef] [PubMed]
[17] Hong, K., Hu, L., Liu, X., Simon, J.M., Ptacek, T.S., Zheng, X., et al. (2020) Usp37 Promotes Deubiquitination of HIF2α in Kidney Cancer. Proceedings of the National Academy of Sciences, 117, 13023-13032. [Google Scholar] [CrossRef] [PubMed]
[18] Liu, C., Liu, L., Wang, K., Li, X., Ge, L., Ma, R., et al. (2020) VHL-Hif-2α Axis-Induced SMYD3 Upregulation Drives Renal Cell Carcinoma Progression via Direct Trans-Activation of EGFR. Oncogene, 39, 4286-4298. [Google Scholar] [CrossRef] [PubMed]
[19] Fan, Y., Ou, L., Fan, J., Li, L., Wu, X., Luo, C., et al. (2019) HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1α/NF-κB Signaling Pathway. Urology, 127, 61-67. [Google Scholar] [CrossRef] [PubMed]
[20] Huang, R.R., Chen, Z., Kroeger, N., Pantuck, A., Said, J., Kluger, H.M., et al. (2024) CD70 Is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 22, 347-353. [Google Scholar] [CrossRef] [PubMed]
[21] Li, X., Wu, Y., Xiao, Z., Liu, Y., Wang, C., Zhou, L., et al. (2024) Long Non-Coding RNA HIF1A-AS2 Promotes Carcinogenesis by Enhancing Gli1-Mediated HIF1α Expression in Clear Cell Renal Cell Carcinoma. Pathology—Research and Practice, 253, Article ID: 154984. [Google Scholar] [CrossRef] [PubMed]
[22] Singh, A., Choudhury, S.D., Singh, P., Singh, V.V., Singh, S.N. and Sharma, A. (2022) KCMF1 Regulates Autophagy and Ion Channels’ Function in Renal Cell Carcinoma: A Future Therapeutic Target. Journal of Cancer Research and Clinical Oncology, 149, 5617-5626. [Google Scholar] [CrossRef] [PubMed]
[23] Liao, M., Li, Y., Xiao, A., Lu, Q., Zeng, H., Qin, H., et al. (2022) HIF-2α-Induced Upregulation of CD36 Promotes the Development of CCRCC. Experimental Cell Research, 421, Article ID: 113389. [Google Scholar] [CrossRef] [PubMed]
[24] Panowski, S.H., Srinivasan, S., Tan, N., et al. (2022) Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma. Cancer Research, 82, 2610-2624. [Google Scholar] [CrossRef] 

为你推荐